- 抑制剂
- 化合物库
- 抗体
- 生物试剂
- qPCR
- 2x SYBR Green qPCR Master Mix
- 2x SYBR Green qPCR Master Mix(Low ROX)
- 2x SYBR Green qPCR Master Mix(High ROX)
- 蛋白实验
- Protein A/G免疫沉淀磁珠
- Anti-DYKDDDDK Tag免疫磁珠
- Anti-DYKDDDDK Tag亲和凝胶
- Anti-Myc免疫磁珠
- Anti-HA免疫磁珠
- 磁力架
- Poly DYKDDDDK Tag多肽
- 细胞核与细胞浆蛋白抽提试剂盒
- 免疫磁珠
- 蛋白酶抑制剂Cocktail
- 蛋白酶抑制剂Cocktail(DMSO储液)
- 磷酸酶抑制剂Cocktail
- 新产品
- 联系我们
TPCA-1
别名: GW683965
TPCA-1 (GW683965)是一种IKK-2抑制剂，无细胞试验中IC50为17.9 nM，抑制NF-κB通路，比作用于IKK-1选择性高22倍。TPCA-1 也是 STAT3 的抑制剂并可促进凋亡。
TPCA-1 Chemical Structure
CAS: 507475-17-4
产品质控
批次：
纯度：
99.85%
99.85
TPCA-1相关产品
相关信号通路图
细胞实验数据示例
| 细胞系 | 实验类型 | 给药浓度 | 孵育时间 | 活性描述 | 文献信息(PMID) |
|---|---|---|---|---|---|
| C57BL/6 mouse BMDM cells | Function assay | 0.5 μM | 1 h | Antiinflammatory activity in C57BL/6 mouse BMDM cells assessed as inhibition of LPS-stimulated TNFalpha production at 0.5 uM pretreated for 1 hr before LPS challenge after 8 to 24 hrs by immunoassay | 22533790 |
| C57BL/6 mouse BMDM cells | Cytotoxicity assay | 24 h | Cytotoxicity against C57BL/6 mouse BMDM cells assessed as LDH release after 24 hrs | 22533790 | |
| MDA-MB-231 | Cytotoxicity assay | 3 days | Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition after 3 days by presto blue dye based plate reader method | 27077228 | |
| TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 29435139 | ||
| DAOY | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 29435139 | ||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 29435139 | ||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | ||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | ||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 29435139 | ||
| NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 29435139 | ||
| U-2 OS | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 29435139 | ||
| Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 29435139 | ||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 29435139 | ||
| NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 29435139 | ||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 29435139 | ||
| Rh18 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 29435139 | ||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | ||
| RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 29435139 | ||
| MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 29435139 | ||
| Rh30 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 29435139 | ||
| Rh41 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 29435139 | ||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) | 29435139 | ||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells | 29435139 | ||
| TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells | 29435139 | ||
| MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells | 29435139 | ||
| U-2 OS | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells | 29435139 | ||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells | 29435139 | ||
| 点击查看更多细胞系数据 | |||||
生物活性
| 产品描述 | TPCA-1 (GW683965)是一种IKK-2抑制剂，无细胞试验中IC50为17.9 nM，抑制NF-κB通路，比作用于IKK-1选择性高22倍。TPCA-1 也是 STAT3 的抑制剂并可促进凋亡。 | ||||||
|---|---|---|---|---|---|---|---|
| 靶点 |
|
| 体外研究(In Vitro) | ||||
| 体外研究活性 | 在时间分辨荧光能量共振转移试验中，TPCA-1抑制人IKK-2活性，IC50为17.9 nM。TPCA-1被证明是ATP竞争性的。此外，TPCA-1对IKK-1和JNK3分别表现出400 nM和3600 nM的IC50值。TPCA-1浓度依赖性抑制TNF-α，IL-6，和IL-8的产生，IC50值分别为170，290，和320 nM。[1] TPCA-1抑制胶质瘤细胞增殖，以及TNF诱导的RelA (p65)核转运和NFκB依赖性IL8基因表达。重要的是，TPCA-1抑制IFN诱导的基因表达，完全抑制MX1和GBP1基因表达，而对ISG15表达仅具有很小的作用。[2] |
|||
|---|---|---|---|---|
| 激酶实验 | IKK-2 试验 | |||
| 重组人IKK-2 (残基1-756)在杆状病毒中以N端GST标记的融合蛋白表达，其活性使用时间分辨荧光共振能量转移测定法进行评估。简而言之，IKK-2 (终浓度5 nM)在试验缓冲液(50 mM HEPES，10 mM MgCl2，1 mM CHAPS，pH 7.4，1 mM DTT 和0.01% w/v BSA)中稀释，加入包含不同浓度化合物或二甲基亚砜(DMSO)载体(终浓度3%)的孔中。加入总体积为30 μL 的GST-IκBα 底物(终浓度25 nM)/ATP (终浓度1 μM)起始反应。反应在室温下培育30分钟，然后加入15 μL 50 mM EDTA终止。加入包含W-1024铕螯合物标记的抗磷酸丝氨酸- IκBα-32/36单克隆抗体12C2，和别藻蓝素标记的抗-GST抗体的检测试剂(15 μL)缓冲液(100 mM HEPES，pH 7.4，150 mM NaCl，和0.1% w/v BSA)，反应在室温下进一步培养60分钟。GST- IκBαis的磷酸化程度以特定665-nm能量转移信号的比率，参考铕620-nm信号，使用Packard探测酶标仪测量。 | ||||
| 细胞实验 | 细胞系 | U87，MT330，SJ-G2，和 GBM6 人胶质瘤细胞系 | ||
| 浓度 | 0-50 μM | |||
| 孵育时间 | 3天 | |||
| 方法 | 将来自储备液(10 mg/mL)的10μL 3-(4,5-二甲基噻唑-2)-2,5-二苯基四氮唑溴盐(MTT)加入包含胶质瘤细胞的96孔板中，并在37 °C下培育2-4小时。氧化的MTT通过将100 μL 10%十二烷基硫酸钠(SDS)加入0.01 N HCL中溶解，板在37 °C下湿润的环境中培养4小时。板于570 nm下在酶标仪上读数。 |
|||
| 体内研究(In Vivo) | ||
| 体内研究活性 | TPCA-1(3, 10, 或20 mg/kg，i.p., b.i.d.)预防性给药，导致小鼠体内胶原诱导性关节炎(CIA)的严重程度剂量依赖性降低。TPCA-1(10 mg/kg, i.p., b.i.d.)导致的显著降低的疾病严重程度和疾病发作的延迟与抗风湿药，与每隔一天预防性给药的作用相当。TPCA-1- 处理的小鼠爪子组织中，p65的细胞核定位，以及IL-1β，IL-6，TNF-α，和干扰素-γ的水平显著降低。此外，TPCA-1给药导致体内胶原诱导的T细胞增殖显著减少。TPCA-1以20 mg/kg，而不是3或10 mg/kg，i.p.，b.i.d.治疗性给药显著降低CIA的严重程度。[1] |
|
|---|---|---|
| 动物实验 | Animal Models | 患有胶原诱导性关节炎的小鼠 |
| Dosages | 3，10，或 20 mg/kg | |
| Administration | 通过腹腔注射给药，每日两次 | |
|
化学信息&溶解度
| 分子量 | 279.29 | 分子式 | C12H10FN3O2S |
| CAS号 | 507475-17-4 | SDF | Download TPCA-1 SDF |
| Smiles | C1=CC(=CC=C1C2=CC(=C(S2)NC(=O)N)C(=O)N)F | ||
| 储存条件(自收到货起) | |||
|
体外溶解度 |
DMSO : 56 mg/mL ( (200.5 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble |
摩尔浓度计算器 |
|
体内溶解配方 现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂 |
动物体内配方计算器 | |||||
实验计算
动物体内配方计算器（澄清溶液）
第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
mg/kg
g
μL
只
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
计算结果：
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；
体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH2O，混匀澄清。
体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。
注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
技术支持
在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。
如果有其他问题，请给我们留言。
* 必填项
